p53 but not bcl-2 is expressed by most cholangiocarcinomas: A study of 28 cases

Histopathology

Volumn 34, Issue 6, 1999, Pages 497-501

  Arora, D S ^a   Ramsdale, J ^a   Lodge, J P A ^a   Wyatt, J I ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

bcl 2; Bile duct; Cholangiocarcinoma; p53; Prognosis; Surgery

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ARTICLE; BILE DUCT CARCINOMA; CANCER INVASION; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033022484     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.1999.00654.x     Document Type: Article

References (17)

1. 1. Terada T, Shimizu K, Izumi R, Nakanuma Y. p53 expression in formalin fixed, paraffin embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating and tissue sections. Meth. Pathol. 1994; 7; 249-252.
2. 2. Ohashi K, Nakajima Y, Kanehiro H et al. Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumour morphology. Gastroenterology 1995; 109; 1612-1617.
3. 3. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S. Mutations of p53 tumour suppressor gene and ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Molec. Carcinogen. 1993; 8; 312-318.
4. 4. Washington K, Gottfried R. Expression of p53 in adenocarcinoma of the gall bladder and bile ducts. Liver 1996; 16; 99-104.
5. 5. Rizzi PM, Ryder SD, Portmann B, Ramage JR, Naoumov NV, Williams R. p53 protein over-expression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996; 38; 265-268.
6. 6. Vautier G, Portmann B, Jenkins D, Ryder SD. p53 mutations in dysplastic and neoplastic bile duct epithelium in primary sclerosing cholangitis. Gut 1998; 42 (Suppl. 1); A50.
7. 7. Terada T, Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen and apoptosis-related antigens (bcl-2, c-myc, ras, Lewis and p53) in human cholangiocarcinomas and hepatocellular carcinomas. Pathol. Internat. 1996; 46; 764-770.
8. 8. Frédéric CL, L'Herminé A, Martin N et al. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am. J. Pathol. 1994; 144; 460-465.
9. 9. Isobe M, Emanuel BS, Givol D, Oren M, Croce CM. Localisation of gene for human p53 tumour antigen to band 17p13. Nature 1986; 320; 84.
10. 10. Vogelstein B. A deadly inheritence. Nature 1990; 348; 681-682.
11. 11. Patel DD, Bhatavdekar JM, Chikhlikar PR et al. Clinical significance of p53, nm23 and bcl-2 in T3-4N1M0 oesophageal carcinomas; an immunohistochemical approach. J. Surg. Oncol. 1997; 65; 111-116.
12. 12. Muller W, Borchard F. Prognostic influence of p53 expression in gastric cancer. J. Pathol. 1996; 178; 255-258.
13. 13. Dergham ST, Dugan MC, Joshi US et al. The clinical significance of p21 (WAF1/CIP-1) and p53 expression in pancreatic carcinoma. Cancer 1997; 80; 372-381.
14. 14. Manne U, Myers RB, Moron C et al. Prognostic significance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Internat. J. Cancer 1997; 74; 346-358.
15. 15. Levine AJ. The p53 tumour-suppressor gene. N. Engl. J. Med. 1992; 326; 1350-1352.
16. 16. Wynford-Thomas D. p53 in tumour pathology: Can we trust immunocytochemistry? J. Pathol. 1992; 166; 329-330.
17. 17. Pezzella F, Gatter K. What is the value of bcl-2 protein detection for histopathologists? Histopathology 1995; 26; 89-93.